Study:
A Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab For Locally Advanced Pancreatic Cancer
Rationale:
Drugs used in chemotherapy, such as capecitabine and gemcitabine, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in
different ways. Some block the ability of tumor cells to grow and spread. Others find tumor
cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also
stop the growth of pancreatic cancer by blocking blood flow to the tumor. Radiation therapy
uses high-energy x-rays to kill tumor cells. Capecitabine may make tumor cells more
sensitive to radiation therapy. Bevacizumab may make tumor cells more sensitive to both
chemotherapy and radiation therapy. Giving chemotherapy and bevacizumab before and after
radiation therapy may kill more tumor cells.
Purpose:
This phase II trial is studying how well giving capecitabine and bevacizumab
together with radiation therapy followed by gemcitabine and bevacizumab works in treating
patients with locally advanced pancreatic cancer that cannot be removed by surgery.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Pancreatic Cancer |
Biological: bevacizumab
Drug: capecitabine
Drug: gemcitabine hydrochloride
Radiation: radiation therapy |
Phase 2 |
Verified by
Radiation Therapy Oncology Group
February, 2006
Sponsored by: Radiation Therapy Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00114179
Study Type: Interventional
Study Design: Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Christopher H. Crane, MD., Study Chair
William F. Regine, MD.,
Howard Safran, MD.,